AIM:To observe the clinical effect of the intravitreal Ranibizumab(IVR)combined with retinal photocoagulation for the neovascular glaucoma(NVG).

METHODS: Clinical data of 30 patients with the neovascular glaucoma(36 eyes)in our hospital from Ocuober 2012 to Sepember 2013 were analyzed retrospectively. All eyes accepted the photocoagulation 7d after IVR(0.05mL/1.25mg). Visual acuity, intraocular pressure(IOP), the degradation of iris neovascularization and complications were observed and compared statistically before treatment and 1wk, 1, 3mo after treatment.

RESULTS: The new vessels on the iris and the angle of anterior chamber regressed completely in all eyes 5d after IVR, the mean time was 3.7±1.4d. The differences were statistically significant when compared IOP(18.2±2.1, 16.8±3.1, 17.2±2.4mmHg,)at 1wk, 1, 3mo postoperatively with 30.5±3.6mmHg preoperatively. The visual acuity of all the eyes was stable and rose slightly.

CONCLUSION: IVB combined with retinal photocoagulation can make the new vessels on the iris and the angle of anterior chamber regression and to lower the IOP. No serious complications were observed after treatment. It is a new security and effective method for neovascular glaucoma.